Inclination of the Researchers for Overcoming Osimertinib Resistance in NSCLC Patients

Inclination of the Researchers for Overcoming Osimertinib Resistance in NSCLC Patients

Release Date: 07-Nov-2020



For the treatment of the patients suffering from EGFR mutant non-small cell lung cancer, Osimertinib brand name Tagrisso has emerged as a frontline treatment option. The drug is believed to overcome the resistance challenge that is developed by the patients suffering from non-small cell lung cancer. By the regulatory body i.e. the US FDA, the drug got approved for the patients suffering from non-small cell lung which have EGFR mutations. It was observed through clinical trials that the drug was able to reduce the risk of progression by a huge percentage when compared with the other drugs available for the cancer. The drug has pre-dominantly reduced the level of resistance developed by the patients. But the widespread use of the drug has resulted in the issue of resistance.

 

Therefore, several studies focused on overcoming the resistance issue has been initiated by the researchers. Therefore, another study called as ORCHARD trial is focused on examining the optimal treatment for patients with EGFR-mutated NSCLC, depending on their underlying resistance mechanism to frontline osimertinib. In the early phase of another study called as CHRYSALIS study was focused on combining the drugs amivantamab and Lazertinib in the NSCLC patients who had relapsed following treatment with Osimertinib. 

 

According to the researchers working on the study, there are numerous ways of finding novel treatments for treating the patients suffering from EGFR mutant non-small cell lung cancer, whereas the drug Osimertinib has just moved the needle. The combination of the drugs with the respective drugs is estimated to help the patients who have the cancer. The primary aim of the study will be observing the combination treatment on the NSCLC patients who have developed resistance. 

Need custom market research solution? We can help you with that too.